In one paragraphArticle in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Mariam R HabilDepartment of Pharmacology and Toxicology, School of Medicine, University of Louisville, Louisville, KY 40202, USA.ORCID 0000-0001-9205-6076 Makayla A StephensDepartment of Pharmacology and Toxicology, School of Medicine, University of Louisville, Louisville, KY 40202, USA.
Alexandra A CassDepartment of Pharmacology and Toxicology, School of Medicine, University of Louisville, Louisville, KY 40202, USA.ORCID 0009-0005-3678-813X Elise M MittlestatDepartment of Pharmacology and Toxicology, School of Medicine, University of Louisville, Louisville, KY 40202, USA.ORCID 0009-0009-9428-6655 Darbie KwonDepartment of Pharmacology and Toxicology, School of Medicine, University of Louisville, Louisville, KY 40202, USA.ORCID 0009-0006-9223-2918 Alexandra EllisonDepartment of Pharmacology and Toxicology, School of Medicine, University of Louisville, Louisville, KY 40202, USA.
J Calvin KouokamDepartment of Pharmacology and Toxicology, School of Medicine, University of Louisville, Louisville, KY 40202, USA.ORCID 0000-0001-8679-2536 David W HeinDepartment of Pharmacology and Toxicology, School of Medicine, University of Louisville, Louisville, KY 40202, USA.ORCID 0000-0003-3261-9775 Funding
Superfund Training CoreP42ES023716 · NIEHS · UNIVERSITY OF LOUISVILLE · PI HEIN, DAVID W · 2017 to 2025
$18.1MNIEHS NIH HHS P42 ES023716United States Public Health Service P20-GM113226United States Public Health Service P30-ES030283United States Public Health Service P42-ES023716
6 · The paper itselfAbstract
Hydralazine is widely used to treat hypertension during pregnancy and has epigenetic effects in cancer therapy. Cryoplatable human hepatocytes showed concentration-dependent increase in DNA damage response (linear trend
Indexed as
DNA DamageHepatocytesHydralazineOxidative StressAcetylationAnimalsArylamine N-AcetyltransferaseCell SurvivalCHO CellsCricetinaeCricetulusCytochrome P-450 CYP1A2HumansArylamine N-AcetyltransferaseCYP1A2 protein, humanCytochrome P-450 CYP1A2HydralazineNAT2 protein, humanantioxidant/ROSAP sitesDNA damagehuman hepatocyteshydralazineγH2AX in-cell western assay
Identifiers
PMID42072683
PMCPMC13114133
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390